SCHEMBL4884271

SCHEMBL4884271

FC(F)(F)c1c(-c2ccccc2)[nH]c2ccccc12

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 3/20 0.55
▸ ESR2 Q92731 3/20 0.55
▸ CYP19A1 P11511 1/20 0.49
▸ NPSR1 Q6W5P4 2/20 0.46
▸ KIF11 P52732 3/20 0.44
▸ ALDH1A1 P00352 4/20 0.44
▸ KDM4E B2RXH2 3/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ MAPT P10636 2/20 0.44
▸ GPR3 P46089 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ CNR1 P21554 1/20 0.43
▸ HTR2A P28223 2/20 0.42
▸ HTR2C P28335 2/20 0.42
▸ KCNH2 Q12809 1/20 0.42
▸ GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2791547 0.82 CYP11B1 (0.61) CYP19A1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL13024122 0.81 ESR1 (0.60) ESR1ESR2CYP19A1NPSR1KIF11
SCHEMBL7915425 0.79 ESR1 (0.53) ESR1ESR2CYP19A1NPSR1ALDH1A1
SCHEMBL1605900 0.75 CYP11B1 (0.43) NPSR1KIF11ALDH1A1KDM4EMEN1
SCHEMBL24611517 0.74 AHR (0.55) NPSR1KIF11ALDH1A1KDM4EMEN1
SCHEMBL29498718 0.74 MEN1 (0.58) NPSR1KIF11ALDH1A1KDM4EMEN1
SCHEMBL26135839 0.74 ALDH1A1 (0.39) ESR1ESR2KIF11ALDH1A1KDM4E
SCHEMBL31628866 0.74 PBRM1 (0.46) ALDH1A1KDM4EMEN1KMT2AMAPT
SCHEMBL9755705 0.74 ESR1 (0.47) ESR1ESR2CYP19A1NPSR1KIF11
SCHEMBL27882145 0.74 ESR1 (0.61) ESR1ESR2CYP19A1NPSR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200216430-A1 CATALYST-FREE AND REDOX-NEUTRAL INNATE TRIFLUOROMETHYLATION AND ALKYLATION OF (HETERO)AROMATICS ENABLED BY LIGHT THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2020-07-09 — — US disclosed
US-20200216430-A1 CATALYST-FREE AND REDOX-NEUTRAL INNATE TRIFLUOROMETHYLATION AND ALKYLATION OF (HETERO)AROMATICS ENABLED BY LIGHT THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2020-07-09 — — US disclosed
WO-2019060998-A1 CATALYST-FREE AND REDOX-NEUTRAL INNATE TRIFLUOROMETHYLATION AND ALKYLATION OF (HETERO)AROMATICS ENABLED BY LIGHT THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2019-04-04 — — WO disclosed
US-20080039625-A1 Screening Methods LAUTENS MARK 2008-02-14 — — US disclosed
US-20080039625-A1 Screening Methods LAUTENS MARK 2008-02-14 — — US disclosed
US-20080039625-A1 Screening Methods LAUTENS MARK 2008-02-14 — — US disclosed
EP-1817283-A1 2-SUBSTITUTED INDOLES, THEIR PRECURSORS AND NOVEL PROCESSES FOR THE PREPARATION THEREOF Lautens, Mark (CA) 2007-08-15 — — EP disclosed
WO-2006047888-A1 2-SUBSTITUTED INDOLES, THEIR PRECURSORS AND NOVEL PROCESSES FOR THE PREPARATION THEREOF LAUTENS MARK (CA) 2006-05-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039625-A1 Screening Methods CBR3, ZKSCAN2, CRBN ESR1 3078/4885ESR2 3149/4885CYP19A1 1968/4885
US-20200216430-A1 CATALYST-FREE AND REDOX-NEUTRAL INNATE TRIFLUOROMETHYLATION AND ALKYLATION OF (HETERO)AROMATICS ENABLED BY LIGHT CYBB, NOX4, NOX3 ESR1 1717/4885ESR2 1903/4885CYP19A1 1085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback